EA

Ektaben Anishkumar Parikh

Active Director Director DIN 10492849
DIN 10492849 First appointment Feb 2024 Primary industry Paper
Unlock full profile Investments Β· shareholding Β· contact details
Current companies 1 active board seats
Total affiliations 1 Since Feb 2024
Shareholding value β€’β€’β€’β€’ Premium profile

About Ektaben Anishkumar Parikh

Data last updated:

Ektaben Anishkumar Parikh is a Director at Mahed Pharma Limited (since 2024). The company operates in Paper.

DIN 10492849
Primary Designation Director
Industry Paper
First Appointment 05 Feb 2024
Oldest Company Age 2 yrs

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Mahed Pharma Limited U21009GJ2024PLC148320
Director05 Feb 20242024Active

Board colleagues of Ektaben Anishkumar Parikh

NameDINCompanyDesignation
Anishkumar Parikh02268701Mahed Pharma LimitedDirector
Sunilkumar Sudhirkumar Shah10492850Mahed Pharma LimitedDirector

Directorship timeline

Open interactive timeline →
Mahed Pharma Limited
Premium access

Shareholding and investment profile for Ektaben Anishkumar Parikh

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Ektaben Anishkumar Parikh

Ektaben Anishkumar Parikh currently holds 1 directorship: Mahed Pharma Limited (Director, since 05 Feb 2024).

Ektaben Anishkumar Parikh was first appointed on 05 Feb 2024 as Director at Mahed Pharma Limited.

The current boards of Ektaben Anishkumar Parikh's companies include Anishkumar Parikh (Mahed Pharma Limited), Sunilkumar Sudhirkumar Shah (Mahed Pharma Limited).

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available